Author

Sophie Dennetiere

Observed name: Sophie Dennetière

Institution: Centre Hospitalier de Roubaix

Observed institution: Centre Hospitalier de Roubaix

ORCID: 0009-0000-7493-4285

Observed ORCID: 0009-0000-7493-4285

OpenAlex ID: A5109688987

Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study

2024 · Caroline Dartigeas, Anne Quinquenel, et al. · Annals of Hematology · 10

Diagnostic relevance of SH2B3 mutations in suspected myeloid malignancies and acute leukemia: insights from a large-scale NGS-based screening study

2025 · Leïla Ben Dhia, Mathieu Wemeau, et al. · Blood Cancer Journal · 3

Comparison of axicabtagene ciloleucel to standard regimens as second line treatment for large B cell lymphoma in real life: A lysa study from descar-T and realysa registries

2025 · Gabriel Brisou, Aurelien Belot, et al. · Blood · 1

Diagnostic relevance of SH2B3 mutations in suspected myeloid malignancies: Insights from a large-scale NGS-based screening study

2025 · Leïla BEN DHIA, Mathieu Wemeau, et al. · Blood · 1

Recommandations du Groupe Francophone des Myélodysplasies (GFM) - Approche diagnostique et prise en charge des syndromes myélodysplasiques, des leucémies myélomonocytaires chroniques et du syndrome VEXAS

2026 · Sophie Park, Lionel Adès, et al. · Bulletin du Cancer

Outcomes of refractory and early‐relapsed large B‐cell lymphoma patients after first‐line treatment in the prospective Real ‐world dAta in LYmphoma patients and Survival in Adults ( REALYSA ) cohort in the pre‐ CAR T era

2026 · Stéphanie Guidez, Aurélien Belot, et al. · British Journal of Haematology

Works count: 6

Citation count: 15

H-index: 2

I10-index: 1